A reply to questions raised about FEV1Q and bronchodilator responsiveness

Martin R Miller; Sanja Stanojevic; David A Kaminsky; Bruce R Thompson

doi:10.1183/13993003.02025-2022

A reply to questions raised about FEV₁Q and bronchodilator responsiveness

Eur Respir J. 2023 Jan 19;61(1):2202025. doi: 10.1183/13993003.02025-2022. Print 2023 Jan.

Authors

Martin R Miller¹, Sanja Stanojevic², David A Kaminsky³, Bruce R Thompson⁴

Affiliations

¹ Institute of Applied Health Research, University of Birmingham, Birmingham, UK mrmc2oho@gmail.com.
² Department of Community Health and Epidemiology, Dalhousie University, Halifax, NS, Canada.
³ Pulmonary Disease and Critical Care Medicine, University of Vermont Larner College of Medicine, Burlington, VT, USA.
⁴ Physiology Service, Department of Respiratory Medicine, The Alfred Hospital and School of Health Sciences, Swinburne University of Technology, Melbourne, Australia.

Abstract

The recent ATS/ERS technical standard on pulmonary function test interpretive strategies is based on the available evidence https://bit.ly/3hgQsm1

Publication types

Letter
Comment

MeSH terms

Bronchodilator Agents* / therapeutic use
Humans
Pulmonary Disease, Chronic Obstructive* / drug therapy
Pulmonary Disease, Chronic Obstructive* / physiopathology
Respiratory Function Tests

Substances

Bronchodilator Agents